AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

Nuclidium has raised 79 million Swiss francs ($99 million) as the Swiss and German biotech looks to continue the clinical ...

AstraZeneca may have washed its hands of AZD4041 after the potential opioid use disorder (OUD) therapy demonstrated a drug-drug interaction last year, but the pharma’s development partner Eolas The | ...

Analysts are keeping the faith in Ultragenyx’s brittle bone disease medicines despite the monoclonal antibody failing to score an early outright win in an ongoing phase 3 trail. | Analysts are keeping ...

Two veteran biotech investors have reunited to form a new venture capital firm focusing on autoimmune diseases. Steven St. | ...

Scientists have identified a new class of compounds capable of partially clearing the tropical parasite that causes Chagas ...

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. | Rhythm Pharmaceuticals’ push to ...

Medtronic reported that it has begun testing an expansion of its renal denervation approach for dropping stubbornly high ...

Mendaera has claimed an FDA clearance for its handheld robotic needle delivery system, for precision placement guided by ...

Novartis has inked a deal with China-based biotech Sironax that gives the pharma the exclusive option to acquire the ...

Revolution Medicines has zeroed in on Iambic Therapeutics’ AI drug discovery platform, striking a multi-year technology and research collaboration that gives Iambic the chance to earn up to $25 mil | ...

Jasper Therapeutics’ dud drug lot has cost half of the biotech's employees their jobs. | Jasper Therapeutics’ dud drug lot ...